Insulin human
- Generic Name
- Insulin human
- Brand Names
- Actraphane, Actrapid, Afrezza, Entuzity, Exubera, Humulin, Humulin N, Humulin R, Insulatard, Insuman, Myxredlin, Novolin, Novolin N, Novolin R, Protaphane, Mixtard
- Drug Type
- Biotech
- Chemical Formula
- -
- CAS Number
- 11061-68-0
- Unique Ingredient Identifier
- 1Y17CTI5SR
- Background
Human Insulin, also known as Regular Insulin, is a short-acting form of insulin used for the treatment of hyperglycemia caused by Type 1 and Type 2 Diabetes. Human insulin is produced by recombinant DNA technology and is identical to endogenously produced insulin. Typically prescribed for the management of diabetes mellitus, insulin is a peptide hormone prod...
- Indication
Human insulin is indicated to improve glycemic control in adults and pediatric patients with diabetes mellitus.
- Associated Conditions
- Diabetes Mellitus, Type 1 Diabetes Mellitus
- Associated Therapies
- -
Prospective Influence of Bedtime Insulin Glargine on Mobilization and Function of Endothelial Progenitor Cells
- First Posted Date
- 2007-08-31
- Last Posted Date
- 2009-02-13
- Lead Sponsor
- Heidelberg University
- Target Recruit Count
- 75
- Registration Number
- NCT00523393
- Locations
- 🇩🇪
University Clinics Heidelberg, Dept. Medicine1, Heidelberg, Germany
Efficacy and Safety of Insulin Aspart vs. Human Insulin During Pregnancy by Women With Type 1 Diabetes
- Conditions
- First Posted Date
- 2006-08-17
- Last Posted Date
- 2016-12-21
- Lead Sponsor
- Novo Nordisk A/S
- Target Recruit Count
- 419
- Registration Number
- NCT00365170
- Locations
- 🇬🇧
Novo Nordisk Investigational Site, Worcester, United Kingdom
Exubera vs Lispro in a Lantus-based Regimen for Improved Glycemic Control in Type 2 Diabetes
- First Posted Date
- 2006-07-04
- Last Posted Date
- 2010-03-16
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 191
- Registration Number
- NCT00348374
- Locations
- 🇵🇷
Pfizer Investigational Site, San Juan, Puerto Rico
Study to Estimate the Effects of Inhaled Versus Intravenous (IV) Infusion of Human Insulin in Subjects With Type 1 Diabetes
- Conditions
- First Posted Date
- 2006-04-19
- Last Posted Date
- 2008-02-18
- Lead Sponsor
- University of Pittsburgh
- Target Recruit Count
- 12
- Registration Number
- NCT00315952
- Locations
- 🇺🇸
University of Pittsburgh, Pittsburgh, Pennsylvania, United States
The Impact of Renin-angiotensin System on Brain Activation During Hypoglycaemia in Healthy Men, a PET Study
- First Posted Date
- 2005-12-13
- Last Posted Date
- 2017-03-29
- Lead Sponsor
- Hypoglycaemia Research Group
- Target Recruit Count
- 20
- Registration Number
- NCT00264641
- Locations
- 🇩🇰
Medical Department I, Hillerød Hospital, Hillerød, Denmark
Insulin Aspart vs. Insulin Lispro vs. Regular Insulin in Paediatric Population
- Conditions
- First Posted Date
- 2003-10-24
- Last Posted Date
- 2016-12-22
- Lead Sponsor
- Novo Nordisk A/S
- Target Recruit Count
- 378
- Registration Number
- NCT00071448
- Locations
- 🇺🇸
Novo Nordisk Investigational Site, Madison, Wisconsin, United States
Safety and Efficacy of Insulin Aspart vs. Regular Human Insulin in Gestational Diabetes
- Conditions
- First Posted Date
- 2003-07-18
- Last Posted Date
- 2016-12-22
- Lead Sponsor
- Novo Nordisk A/S
- Target Recruit Count
- 27
- Registration Number
- NCT00065130
- Locations
- 🇺🇸
Novo Nordisk Investigational Site, Santa Barbara, California, United States
Compare Blood Sugar Level Between Lantus in the Morning and Other Insulins in Type 1 Diabetes Adolescents
- Conditions
- First Posted Date
- 2002-10-02
- Last Posted Date
- 2011-01-11
- Lead Sponsor
- Sanofi
- Target Recruit Count
- 250
- Registration Number
- NCT00046501
- Locations
- 🇺🇸
Aventis, Bridgewater, New Jersey, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.